Fig. 2From: Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndromePrediction of neutrophil count change when 5Â mg/m2 dose is given for five consecutive days with 4-week interval. (From 1000 simulations using the final PK-PD model)Back to article page